Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria

Table 2

Randomized, double-blinded, parallel-group, placebo-controlled comparative studies of bilastine with other antihistamines: study characteristics and results of primary efficacy outcome measures.

Study	Indication	Primary outcome	Arm 1; 𝑁	Arm 2; 𝑁	Arm 3; 𝑁	Results for primary outcome
[14]	Seasonal allergic rhinitis	AUC for TSS from baseline ⇒ 14 days	Bilastine 20 mg; 233	Desloratadine 5 mg; 242	Placebo; 245	Bilastine significantly better than placebo; Bilastine versus desloratadine: NS
[15]	Seasonal allergic rhinitis	AUC for TSS from baseline ⇒ 14 days	Bilastine 20 mg; 227	Cetirizine 10 mg; 228	Placebo; 226	Bilastine significantly better than placebo; Bilastine versus cetirizine: NS
[16]	Perennial allergic rhinitis	AUC for TSS from baseline ⇒ 28 days	Bilastine 20 mg; 214	Cetirizine 10 mg; 217	Placebo; 219	Bilastine versus cetirizine and placebo: NS
[17]	Chronic idiopathic urticaria	Change in TSS from baseline ⇒ 28 days	Bilastine 20 mg; 173	Levocetirizine 5 mg; 165	Placebo; 184	Bilastine significantly better than placebo; Bilastine versus levocetirizine: NS

AUC: area under curve; TSS: total symptom score; NS: not statistically significantly better.